CVS Health (NYSE: CVS) Executive Buys $2 Million in Shares Amidst Strategic Separation Plans

• Insider Confidence: A CVS Health (NYSE: CVS) executive recently purchased over $2.00 million in company shares, signaling confidence.
• Strategic Restructuring: CVS Health plans to separate its retail pharmacy business by the first half of 2028, creating two publicly traded entities.
• Strong Financials & Valuation: The company reported solid Q3 2026 results, and a sum-of-the-parts analysis suggests potential upside for CVS Health stock.

CVS Health executive vice president and group president Prem S. Shah purchases 23,855 common shares at $83.90 each on November 6, 2026. The roughly $2.00 million purchase brings his reported holdings to approximately 88,516 shares. CVS Health operates retail pharmacies, health insurance, pharmacy benefit services and care businesses.

The purchase comes as CVS plans to separate its retail pharmacy business by the first half of 2028. The plan creates two publicly traded companies in a tax-free transaction, subject to customary conditions. The continuing CVS Health retains Aetna, Caremark and its care businesses, while CVS Pharmacy contains the retail pharmacies and clinics.

CVS reports third-quarter 2026 revenue of $108.40 billion, up 5.40%, and adjusted earnings per share of $2.09, up 30.70%. It expects full-year 2026 adjusted earnings of at least $8.20 per share. Adjusted earnings exclude certain items to show what the company considers its underlying performance.

A sum-of-the-parts analysis values a company by estimating what its businesses are worth separately. As highlighted by Seeking Alpha, that approach puts CVS’s estimated value at $90.00–$100.00 per share, or 13%–25% above levels at the time of the analysis. This is an estimate, not a guaranteed outcome from the split.

CVS also has an $11.50 billion share buyback authorization. Buybacks reduce shares outstanding when the company purchases its own stock, which can increase earnings per remaining share. The planned separation still carries costs and execution questions, as highlighted by Zacks Investment Research.